Thorlef Spickschen - Clovis Oncology Independent Director
| CLVSDelisted Stock | USD 0.09 0.02 24.00% |
Director
Dr. Thorlef Spickschen is Independent Director of the Company. From 2005 to 2012, Dr. Spickschen was chairman of Biotest AG, a publiclytraded biotechnology company in Germany. From 1994 to 2001, he was chairman and chief executive officer of BASF PharmaKnoll AG. From 1984 to 1994, Dr. Spickschen worked with Boehringer Mannheim GmbH, where he was responsible for sales and marketing and was chairman of its Executive Board since 1990. From 1976 to 1984, Dr. Spickschen was Managing Director, Germany and Central Europe for Eli Lilly Co. Dr. Spickschen is currently chairman of the advisory board of Heidelberg Innovation, a VC firm in life scienceshealthcare, and chairman of Verein Deutsche Nierenstiftung, sponsoring the German kidney foundation. Dr. Spickschen also served on the board of directors for Pharmion Corporation from December 2001 through the companys acquisition in 2008 since 2009.
| Age | 77 |
| Tenure | 15 years |
| Professional Marks | Ph.D |
| Phone | 303 625 5000 |
| Web | https://www.clovisoncology.com |
Clovis Oncology Management Efficiency
The company has return on total asset (ROA) of (0.3018) % which means that it has lost $0.3018 on every $100 spent on assets. This is way below average. Clovis Oncology's management efficiency ratios could be used to measure how well Clovis Oncology manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 436.77 M in liabilities with Debt to Equity (D/E) ratio of 810.0, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Clovis Oncology has a current ratio of 1.15, suggesting that it is in a questionable position to pay out its financial obligations when due. Debt can assist Clovis Oncology until it has trouble settling it off, either with new capital or with free cash flow. So, Clovis Oncology's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Clovis Oncology sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Clovis to invest in growth at high rates of return. When we think about Clovis Oncology's use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Nobuhisa Ikawa | NH Foods Ltd | 62 | |
| Andy Ballard | Dominos Pizza | 41 | |
| Arthur Schaier | Hanover Foods | 66 | |
| Jeffrey Flug | Shake Shack | 58 | |
| James Sturgill | Hanover Foods | 67 | |
| Cyril Noel | Hanover Foods | 83 | |
| Clayton Rohrbach | Hanover Foods | 88 | |
| Yasuko Kono | NH Foods Ltd | 61 | |
| Jose Miron | Marfrig Global Foods | 52 | |
| Keiji Maeda | NH Foods Ltd | N/A | |
| Nobuyuki Tazawa | NH Foods Ltd | N/A | |
| Anna Fieler | Shake Shack | 48 | |
| Gregory Trojan | Dominos Pizza | 56 | |
| Hitoshi Yao | NH Foods Ltd | N/A | |
| Richard Federico | Dominos Pizza | 66 | |
| Marcelo Correa | Marfrig Global Foods | N/A | |
| Koichi Ohyama | NH Foods Ltd | N/A | |
| Carlos Langoni | Marfrig Global Foods | 73 | |
| Kazunori Shinohara | NH Foods Ltd | 63 | |
| Evan Guillemin | Shake Shack | 49 | |
| Andrew Ballard | Dominos Pizza | 45 | |
Management Performance
| Return On Asset | -0.3 |
Clovis Oncology Leadership Team
Elected by the shareholders, the Clovis Oncology's board of directors comprises two types of representatives: Clovis Oncology inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Clovis. The board's role is to monitor Clovis Oncology's management team and ensure that shareholders' interests are well served. Clovis Oncology's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Clovis Oncology's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Anna Sussman, VP Relations | ||
| Thorlef Spickschen, Independent Director | ||
| BSc BSc, Exec Officer | ||
| Brian Atwood, Independent Director | ||
| Paul Klingenstein, Independent Director | ||
| Paul Gross, Executive Vice President Chief Compliance Officer, General Counsel | ||
| Robert Azelby, Director | ||
| Dale Hooks, Senior Vice President Chief Commercial Officer | ||
| Thomas BSc, Ex Officer | ||
| Patrick MA, CEO, CoFounder | ||
| Breanna Burkart, Sr. Director of Investor Relations | ||
| Patrick Mahaffy, President CEO, Director | ||
| Gillian IversRead, Executive Vice President - Technical Operations, Chief Regulatory Officer | ||
| Michael Barrett, Independent Chairman of the Board | ||
| James Blair, Independent Director | ||
| James Barrett, Independent Chairman of the Board | ||
| Richard Fair, Director | ||
| Edward McKinley, Independent Director | ||
| MB BSc, Chief Medical Officer and Executive VP of Clinical and Preclinical Devel. and Pharmacovigilance | ||
| Keith Flaherty, Director | ||
| Lindsey Rolfe, Chief Medical Officer, Executive Vice President - Clinical and Preclinical Development & Pharmacovigilance | ||
| Steven Hoerter, Chief Commercial Officer and Executive VP | ||
| Erle Mast, Co-Founder, CFO, Executive VP and Secretary | ||
| Ginger Graham, Independent Director | ||
| Ann Bozeman, Executive Vice President of Human Resources | ||
| Daniel Muehl, Principal Financial Officer, Principal Accounting Officer |
Clovis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Clovis Oncology a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.3 | |||
| Profit Margin | (1.89) % | |||
| Operating Margin | (1.55) % | |||
| Current Valuation | 651.32 M | |||
| Shares Outstanding | 144.96 M | |||
| Shares Owned By Insiders | 1.43 % | |||
| Shares Owned By Institutions | 25.89 % | |||
| Number Of Shares Shorted | 28.49 M | |||
| Price To Earning | (8.65) X | |||
| Price To Sales | 0.11 X |
Pair Trading with Clovis Oncology
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Clovis Oncology position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Clovis Oncology will appreciate offsetting losses from the drop in the long position's value.Moving against Clovis Stock
| 0.78 | WMT | Walmart Financial Report 16th of May 2024 | PairCorr |
| 0.77 | AXP | American Express Financial Report 19th of July 2024 | PairCorr |
| 0.65 | GE | GE Aerospace Financial Report 23rd of July 2024 | PairCorr |
| 0.64 | CAT | Caterpillar Earnings Call Tomorrow | PairCorr |
| 0.63 | CVX | Chevron Corp Earnings Call This Week | PairCorr |
The ability to find closely correlated positions to Clovis Oncology could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Clovis Oncology when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Clovis Oncology - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Clovis Oncology to buy it.
The correlation of Clovis Oncology is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Clovis Oncology moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Clovis Oncology moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Clovis Oncology can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in Clovis Stock
If you are still planning to invest in Clovis Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Clovis Oncology's history and understand the potential risks before investing.
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios |